You leave your first appointment knowing exactly how to manage the most common side effects

Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods

Many users report increased energy and slight weight changes within the first few weeks
Translation: a meaningful fraction of what the clinical trial literature has called "lean mass loss" on GLP-1s isn't muscle
Choosing a trusted provider ensures both safety and effectiveness
If you have insurance coverage for Zepbound, you can pay as low as $25 for a 1, 2, or 3-month supply